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Duodenal ulcer: Daily maintenance treatment with the anti-secretory drugs, histamine H2 receptor antagonists and proton pump blockers, controls duodenal ulcer effectively, markedly reducing relapse rate at one year after treatment from about 75 percent to 15 to 20 percent (and to about 10 percent on proton pump blockers). In contrast, Helicobacter pylori eradication with a one to two week course of treatment yields prolonged remission or cure. The consequent reduction in drug costs in individual patients, however, has been exceeded by increasing community use on the more expensive proton pump blockers for the treatment of gastroesophageal reflux disease. The marked decline in elective surgery since the introduction of histamine H2 receptor antagonists is commonly attributed to the power of these drugs. The fall, however, had started much earlier, indicating that the decline is due to changing natural history. In contrast, complication rates remain unaltered. An increasing proportion of newly diagnosed duodenal ulcer patients are elderly, and more of them now present for the first time with complications (in this center, about 40 percent), which consequently cannot be forestalled. Thus, duodenal ulcer disease is likely to remain a problem and in many will be a serious illness.
Gastroesophageal reflux disease: The proton pump blockers have revolutionized the treatment of gastroesophageal reflux disease. In clinical trials they have proven markedly superior to the histamine H2 receptor antagonists in healing (at eight weeks, 80 to 90 percent vs. 50 to 60 percent), symptom relief, prevention of relapse on maintenance therapy and cost-effectiveness. However, several issues remain. The prevalence of gastroesophageal reflux disease seems to be rising and is now probably the commonest acid-peptic disease encountered in the West. Most clinical trials comparing proton pump blockers vs. histamine H2 receptor antagonists have been done in patients with erosive esophagitis, whereas the majority (50 to 60 percent) of patients with gastroesophageal reflux disease have milder, generally non-erosive, disease. The therapeutic gain of proton pump blockers diminishes in mild disease so may not be worth the higher drug costs. This is an important area for investigation. The majority of patients with erosive esophagitis relapse when treatment is stopped (about 75 percent at one year). Relapse is markedly reduced (to 20 to 25 percent) by daily maintenance treatment with proton pump blockers. Mild disease relapses less often, so longterm therapy by intermittent treatment may prove acceptable and more costeffective than maintenance treatment. This strategy remains unexplored in trials. The ideal profile of an anti-secretory drug for intermittent treatment would combine rapid onset of action (similar to histamine H2 receptor antagonists) with powerful effect (as with proton pump blockers). The new class of drug, the reversible proton pump blocker (e.g., BY841) approaches this requirement.
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Results from several studies on long-term maintenance treatment with low dose H2RA confirmed their continued efficacy (for as long as the patients remained on treatment) [3] [4] [5] [6] [7] , the cumulative symptomatic relapse rate at one year off therapy (or on placebo) being 50 to 80 percent compared with only five to 20 percent on treatment. Most relapses on therapy occur in the first two years; after five years the relapse rate in two studies was only 28 percent on 400 mg cimetidine nightly [4] and 39 percent on 150 mg ranitidine nightly [7] . However, in the longest follow-up study so far, the relapse rate on 150 mg ranitidine nightly after nine years was a mere 13 percent [5] . Interruption of treatment is followed by relapse (cumulatively, about 80 percent at five years) [8] ; i.e., the disease is only controlled, not cured, the benefit lasting only for as long as the patient continues treatment ("once he's stopped the drug, he starts where he left off" as a thoughtful editorial written as far back as 1978 put it) [9] . However, from early days there were reports that maintenance treatment lasting from one to five years may alter the natural history of the disease, reflected by reduced relapse rate (compared with the pre-treatment pattern) when therapy is stopped [10, 11] .
Although symptomatic relapse rate was much reduced on maintenance treatment (see above), periodic endoscopic checks in asymptomatic patients showed that silent but active disease was common: for every patient with symptomatic recurrence, another would have silent disease. Thus the treatment seemed more effective in preventing symptom recurrence than in controlling the disease process [4, 12] . H2RA maintenance therapy at a higher (healing) dose (e.g., 0.8 to 1 g cimetidine, 0.3 g ranitidine ) showed still further reduction in relapse rates in some studies [13] but not in others [14] .
Maintenance therapy with PPB is effective, as would be predicted from the powerful anti-secretory effect, although there are few studies comparing them against H2RA [15] [16] [17] [18] [19] [20] . One such study is our own investigation in very aggressive DU; cumulative relapse on 150 mg ranitidine at one year was 54 percent compared with 19 percent on 10 mg omeprazole [21] . One reason for the dearth of comparative studies is that interest has shifted to H. pylori treatment to achieve long-term control.
Prolonged maintenance therapy with H2RA has proven safe, and there is no reason to believe the same will not apply to the PPB. Intermittent treatment aims at rapidly relieving symptoms and healing the ulcer in each relapse without attempting to suppress the disease over the long term. Contrary to earlier views, the majority of patients have fewer than two relapses per year, so each episode can be treated with a short healing course of H2RA as and when needed [1] . Intermittent treatment with omeprazole gave even better results than with cimetidine [22] . Though Finally, a variant of intermittent treatment is "symptomatic self-care," the objective of which aims to relieve symptoms only, the patiept titrating his/her own intake of tablets.
This strategy is suited for patients with mild disease [24] (i.e., patients with infrequent, short-lived, easily controlled symptoms and without a history of ulcer complications). ANTI-HELICOBACTER PYLORI THERAPY This novel treatment exploded into the recently-stabilized world of ulcer control with anti-secretory therapy and has rapidly and radically changed management. Successful bacterial eradication holds the glittering prospects of short-term treatment giving prolonged remission and probably cure. This, in turn, would prevent ulcer complications. By removing the need for maintenance treatment, huge savings in drug costs would be made [25] . Have these come to pass? The proven benefits of H. pylori eradication
The long-term outcome: Cure: The early promise of prolonged DU remission after H. pylori eradication based on studies with one or two year follow-up [26, 27] has recently been confirmed in two studies with longer follow-up: 5.1 to 7.6 years (mean: 6.5 years) [28] and 1.4 to 10.9 years (mean: 4.7 years) [29] -. Recrudescence and re-infection rates are low, probably between one to two percent per year [30, 31] . This minority is at risk of reulceration and needs further eradication therapy or maintenance treatment. For the majority, it seems reasonable to assume further anti-secretory therapy for ulcer disease is no longer required once the organism has been eradicated.
The abolition of complications: Three studies have shown significant reduction of rebleeding after successful H. pylori eradication in patients with peptic ulcer. In a small study (n = 31), 29 percent re-bled on maintenance 300 mg ranitidine vs. none after H. pylori eradication [32] ; in another (n = 66), 38 percent bled again after failed H. pyloni eradication but none after successful treatment [33] . In the largest study (n = 125), 12 percent bled on maintenance 150 mg ranitidine or 20 mg omeprazole daily vs. only 2.3 percent after eradication treatment [34] . Therefore, H. pylori eradication greatly reduces or abolishes risk of further hemorrhage in patients known to have ulcer disease. Curiously, H. pylori is less commonly present in patients with complicated ulcer than in the majority who present with dyspepsia and pain, so the benefits of successful treatment would be expected only in those who harbor the organism [35] [36] [37] [38] [31] . A similar trend was seen in a large community program, where 706 patients were treated. A subset of 163 was followed for a mean of eight months (three months to two and a half years). Intermittent heartburn, the cardinal symptom of reflux disease, continued in 55 percent of those with persistent infection but also in 39 percent of patients with confirmed eradication. Furthermore, after anti-H. pylori therapy, 67 percent with persistent infection had further anti-ulcer treatment from their doctor, as might be expected, but so did 19 percent following successful therapy [39] .
We have also observed in this center that GERD develops on a background of DU. For example, we have identified 1,364 patients with both DU and GERD (representing 12 percent of 11,613 patients, of whom 5,049 had pure DU and 5200 GERD alone). In half, the two conditions were found together at presentation; and in three-quarters of the remainder, GERD developed on follow-up after the patient had presented with DU, necessitating an increase in the dose of H2RA maintenance treatment or a change over to PPB maintenance therapy. Thus, the DU may be cured but further anti-secretory therapy may still be needed if GERD develops. The impact of anti-H. pylori therapy in the community It is reasonably extrapolated from clinical trial results that curing DU in the community will be followed by marked clinical and economic benefits, the latter through reduced long-term drug costs. Indeed, various government bodies are encouraging this treatment approach. The [48] . However, though resistance to nitroimidazoles reduces the efficacy of therapies containing metronidazole or tinidazole, on the whole such treatment remains fairly effective [49] . Possibly of greater concern is the emergence of resistance to the powerful new antibiotic, clarithromycin, which now is increasingly used in anti-H. pylori therapy. In this center, for example, 10 of 70 patients whose H. pylori was not eradicated on pantoprazole + tinidazole + clarithromycin, given for 10 days, had developed resistance to the macrolide, having been sensitive at the start. Such resistance is thought to result from a mutation in the ribosomal RNA of the 23S subunit. The change in antibiotic target renders the drug less efficient and allows survival of mutant clones [50] . Fortunately the resistance is not through plasmids, otherwise the risk of spread of this phenomenon among strains of H. pylori would be greater.
Because of tremendous patient demand for anti-H. pylori treatment, fuelled in part by mass media coverage, general practitioners are under pressure to treat. Increasingly, patients are given treatment without any investigation, not even serology, in the belief "it won't harm and may do good"! Such indiscriminate use may well make antibiotic resistance a bigger problem. [58] [59] [60] [61] [62] [63] [64] [65] [66] . Treatment with PPB is also more cost-effective. Using a model derived from clinical trials and common clinical practice, the drug cost for treating 100 patients over a year (covering healing, relapse, re-healing and maintenance therapy) was $62,272.50 for ranitidine and $47,125 for omeprazole, a reduction of 32 percent [67] . As lansoprazole is a little less expensive than omeprazole, the saving would be even greater. Thus, on grounds of efficacy (in healing, relieving symptoms and preventing relapse by maintenance therapy) and cost-effectiveness, the case for routine use of PPB in GERD is overwhelming. But is this the full story? I suggest not. Some of the issues are discussed below.
THE TREATMENT OF GERD: AREAS TO BE EXPLORED Symptomatic gastroesophageal reflux in patients with normal endoscopy Virtually every trial comparing the PPB against H2RA has been done in patients with erosive esophagitis. This is understandable, for healing of the breached mucosa is clearly recognizable and healing rates, therefore, measurable. In patients with symptomatic gastroesophageal reflux but with normal mucosa, however, symptom improvement is the only quantifiable parameter, and being subjective is less accurate. Yet in reflux disease about half the patients investigated in hospital have normal endoscopy and the proportion in general practice is higher still [68] [69] [70] . For example, in this center only 42 percent of 2,786 patients seen between 1989 to 1993 had erosive changes.
It remains to be proven if the margin of superiQrity of PPB over H2RA in such patients is great enough to make it cost-effective. Results from an important study of patients with erosive esophagitis give some indication what might be expected in less severe disease. In this investigation omeprazole proved superior to ranitidine, as expected. The cost-benefit of omeprazole was greatest in patients with severe erosive changes, when symptoms were very troublesome and index of life-satisfaction low. There was little difference, however, in mild disease; indeed, when the index of life-satisfaction was only slightly reduced, ranitidine proved marginally more cost-effective [71] .
Treatment ofmild gastroesophageal reflux: A recent large study of patients with reflux seen in family practice showed ranitidine was significantly superior to placebo for relieving symptoms and improving the quality of life [72] . Similarly, omeprazole was clearly superior to placebo in the two studies done so far on the treatment of symptomatic reflux in patients with normal endoscopy [73, 74] . Three interesting additional findings emerged from these studies. First, the co-existence of irritable bowel syndrome was associated with a poorer outcome [73] . Second, the diagnostic accuracy of gastroesophageal reflux when judged against the gold standard of esophageal pHmetry varied from 22 to 85 percent across the 16 participating centers [74] . Third, the greater the reflux, the greater was the benefit produced by omeprazole [74] . Irritable bowel syndrome is commonly present in patients with symptomatic gastroesophageal reflux but with normal endoscopy, and reflux itself may be mild despite symptoms. Although the advantage of PPB over placebo in such patients is clear, it cannot necessarily be assumed it will be superior over the H2RA to an extent as to make it cost-effective.
This area was investigated recently in a large study of 994 patients with heartburn seen in general practice, one-third of whom had mild erosive changes. Twenty mg omeprazole, 10 [76] . A similar low relapse rate on placebo was observed in some of the early maintenance studies investigating H2RA [77] .
A recent report described the outcome of a large group of reflux patients followed for up to six years [78] . At the end of the follow-up, one-third of patients were asymptomatic or controlled their symptoms adequately with occasional doses (22 percent) Intermittent treatment: Long-term treatment can be tailored according to the severity of symptoms. Theoretically, patients with mild, infrequent relapses could be treated for short periods and therapy repeated as needed, i.e., intermittent treatment (as has been used in duodenal ulcer). Such an approach is commonly used in general practice, but no study has reported on the outcome of such a policy. However, ranitidine given intermittently has recently proved almost as effective as when given by daily maintenance therapy (unpublished data: personal communication). Intuitively, younger, fitter patients with mild intermittent symptoms and with normal endoscopy, or at most with mild erosive changes, would be selected for such an approach.
Is there still a place for the H2RA? H2RA is more effective than placebo in healing erosive esophagitis (60 percent vs. 30 percent at six to eight weeks) [79] (although not nearly so dramatic as in duodenal ulcer disease, when greater than 80 percent healing would be expected). Low-dose maintenance therapy is generally ineffective in preventing relapse [56] . These observations, together with the superior results achieved with proton pump blockers, created the general impression that H2RA has little or no place in the management of GERD [80] . I believe this conclusion premature for the following reasons:
1. Personal experience: Between 1976 to 1988, 1200 patients in this center were treated satisfactorily with H2RA, principally 1.6 to 2 g cimetidine (or 0.45 to 0.6 g ranitidine ), both in the short-and long-term. The majority, 85 [81] [82] [83] [84] , whereas the PPB lacks such flexibility.
3. Cost-benefit: PPB will remain expensive for several years more, whereas the price of H2RA has fallen markedly. Earlier cost-benefit studies therefore need reassessing. In groups where the clinical advantage of PPB is slight, it may now be more cost-effective to use H2RA. The rising prevalence of GERD It is common experience that reflux disease is now seen more frequently. Figure 1 shows the number of new patients seen in this center each year from 1976 to 1994 with GERD (erosive and non-erosive disease), duodenal and gastric ulcer. The rising numbers of patients with GERD is striking. As this was not a formal epidemiological study, conclusions on changing prevalence have to be tentative and limited. The annual number of endoscopies since 1980 has not changed, so the rise cannot be entirely explained by increasing use of diagnostic methods. Greater awareness of GERD, particularly of nonerosive disease, presumably contributes. However, it is difficult to avoid the possibility that at least a part of the rising numbers results from a true increase in prevalence.
The "middle ground"
Is there a needfor a new molecule? PPB will dominate the treatment of more severe disease; antacid-alginate preparations are perhaps all that are needed in very mild cases, and H2RA, and prokinetics suffice for those with troublesome symptoms. It is the large group in between these two ends where treatment strategies need to be re-examined, and the number of patients in this group is steadily increasing as reflux disease is more frequently diagnosed. Such patients have moderately troublesome symptoms that recur in short relapses followed by longer remissions. The newly diagnosed each year (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) in Rotherham lansoprazole may have a reasonable "first-day" effect and suppresses acid more quickly than omeprazole) [85] . H2RA acts rapidly, particularly the effervescent preparations, but do not sustain pH above 4 for long enough [81] [82] [83] [84] .
A new type of drug, therefore, needs to be considered: Ideally it should: raise the pH above 4 rapidly; sustain this pH level for eight to 10 hours, thus requiring no more than twice daily dosing (and once daily would suffice if symptoms occur only at certain times); have no attenuation of effect in the short-term (say up to four weeks of daily use). The new generation of reversible-PPB approaches this [86] . If the early encouraging results from pharmacological studies are confirmed, these drugs would allow treatment to be tailored more accurately to individual patients' needs. For example, patients with symptoms confined to the daytime need take only a morning dose; and if relapses are short-lived, the drug would be suitable for intermittent therapy. If more frequent and longer periods of treatment become necessary, the patients would have selected themselves for long-term treatment with irreversible PPB. Preliminary anti-H. pylori therapy?
A recent report cautioned on the development of corpus gastritis within eight weeks of omeprazole treatment in patients with H. pylori despite unchanged degree of colonization. This phenomenon was absent in patients who did not harbor the organism. As PPB is often needed for long periods, the investigators recommended eradicating H. pylori first [87] . If this report is confirmed, a new consideration enters the treatment of GERD. CONCLUSIONS 
